Newer Diabetes Meds No Better Than Older, Cheaper Ones

People with diabetes have a multitude of drug options to keep their blood sugar in check from cheap generics that have been around for decades to newer drugs that are pricey to say the least. But the newer drugs are no better at cutting the risk of heart disease, stroke or premature death than the older meds.

Researchers analyzed the results of 301 clinical trials involving more than 120,000 patients. Some of the trials looked at the effectiveness of taking just one diabetes drug, while other examined diabetes therapy with either two or three meds taken together. Overall, 8 different diabetes classes were included.

Interestingly, metformin (also known by brand names Glucophage and Glumetza), a drug that has been around for decades, was better at lowering blood sugar levels than some newer classes of diabetes meds, the researchers reported in the Journal of the American Medical Association.

And as far as extending a person’s life or preventing complications, no single drug or drug combination stood out as better than others.

Recommendations from the American Diabetes Association call for beginning type 2 diabetes treatment with metformin. The study results also showed that metformin has a low risk of hypoglycemia, or a dangerously low drop in blood sugar, compared with other drug classes, especially insulin and sulfonylureas such as Glucotrol (glipizide) and Amaryl (glimepiride).

Metformin is not for everyone, however. Side effects associated with it include gastrointestinal issues such as upset stomach, diarrhea and loss of appetite, as well as muscle pain and sleepiness, causing some patients to discontinue use. People will kidney disease are also advised not to take metformin.


Jonathan Block

Jonathan Block

Jonathan Block is an associate editor at BioCentury, which provides news and information about the biotechnology and pharmaceutical industries. Prior to joining BioCentury in 2019, Jonathan worked for MedShadow as content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.


Did you find this article helpful?

No votes so far! Be the first to rate this post.


Latest News

Belviq, ActiPatch, Free Samples, Dollar Tree Drugs

Belviq, ActiPatch, Free Samples, Dollar Tree Drugs

We knew it was too good to be true – free and cheap drugs aren’t worth it. Also, taking a magic pill to lose weight could give you cancer (!). One ray of sunshine: a pain therapy device using shortwave is now available over-the-counter. Have a lovely Valentine’s Day! Be…

Flouride, PPIs, Breast Density and Prostate Cancer

Flouride, PPIs, Breast Density and Prostate Cancer

Startling news about fluoride, a study encourages more limites use of PPIs, does knowing the density of your breasts matter, and vegetables aren’t helpful in warding off prostate cancer (darn).  Be Well.  Fluoride and Pregnancy The medical community was shocked at the conclusions of two new studies on fluoride’s effect…

  • Advertisement